期刊文献+

P-糖蛋白抑制剂HZ08对裸鼠体内肿瘤多药耐药逆转以及对大鼠肝P450酶影响(英文) 被引量:5

Effects of HZ08,a novel P-glycoprotein inhibitor,on the reversal of P-glycoprotein mediated multidrug resistance in nude mice and cytochrome P-450 activities in rat liver microsomes
下载PDF
导出
摘要 目的:考察P-糖蛋白抑制剂HZ08对K562/ADM接种裸鼠体内肿瘤多药耐药的逆转作用及HZ08对大鼠肝P450酶亚型的影响。方法:K562/ADM接种的裸鼠尾静脉注射HZ08和阿霉素4周,与对照组和阳性药组比较瘤重;HZ08与CYP450亚型特异性底物在大鼠肝微粒体中温孵,与对照组比较测定HZ08对于CYP450亚型的影响。结果:HZ08可显著减小裸鼠体内的瘤重,并对大鼠肝微粒体CYP3A4有较弱的抑制作用,对其他P450酶亚型无显著抑制作用。结论:HZ08在裸鼠体内具有较好的逆转P-糖蛋白介导的肿瘤多药耐药的作用,并且在体外实验中对P450酶具有较小的影响。 Aim: To evaluate the effects of HZ08, a novel P-glycoprotein inhibitor, on reversing tumor resistance of K562/ADM to adriamycin in nude mice and on the activities of cytochromes P-450 (CYP) isoforms. Methods: Nude mice bearing K562/ADM were injected at different doses of HZ08 with adriamycin for 4 weeks. The tumor weights of HZ08 treatment groups were determined and compared to those of the control and positive groups. In addition, the effects of HZ08 were examined on CYP isoforms-mediated metabolism of specific substrates by CYP isoforms in rat liver microsomes in the presence or absence of HZ08. Results: The tumor weights of HZ08 treat- ment groups were significantly decreased and HZ08 was a relatively potent inhibitor of CYP3A4, with no significant effects on other isoforms tested. Conclusion: HZ08 has potent effects on reversing P-glycoprotein mediated tumor multidrug resistance in vivo with little influence on cytochrome P-450 activities of rat liver.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2008年第5期447-452,共6页 Journal of China Pharmaceutical University
基金 supported by the National High Technology Research and Development Program of China(No.2002AA233071)
关键词 HZ08 肿瘤多药耐药 裸鼠 P-糖蛋白抑制剂 肝P450酶 HZ08 tumor muhidrug resistance nude mice P-glycoprotein inhibitor cytochrome P450 enzyme
  • 相关文献

参考文献15

  • 1Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance [ J ] . Curr Opin Gene Dev, 1996,6 ( 5 ) : 610 -617.
  • 2Keppler D, Cui Y, Konig J, et al. Export pumps for anionic conjugates encoded by M RP genes [ J ]. Adv Enzyme Regul, 1999,39: 237 - 246.
  • 3Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil [J]. Cancer Res,1981,41(5) :1 967 - 1 972.
  • 4Ford JM, Bruggemann EP, Pastan I, et al. Cellular and biochemical characterization of thioxanthenes for reversal of muhidrug resistance in human and murine cell lines [ J]. Cancer Res, 1990, 50(6) :1 748 -1 756.
  • 5Bates SE, Wilson WH, Fojo AT, et al. Clinical reversal of multidrug resistance [ J ]. Stem Cells, 1996,14 ( 1 ) :56 - 63.
  • 6Lum BL, Kaubiseh S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate muhidrug resistance [J]. J Clin Oncol, 1992,10(10) :1 635 -1 642.
  • 7Tolcher AW, Cowan KH, Solomon D, et al. A. Phase I crossover study of paclitaxel with R-verapamil in patients with metastatic breast cancer [J]. J Clin Oncol,1996,14(4) :1 173 - 1 184.
  • 8Hardman JG, Limbird LE, Molinoff PB,et al. The Pharmalological Basis of Therapeutics [ M ]. New York : McGraw-Hill, 1996 : 14 -18.
  • 9Szakacs G, Paterson JK, Ludwig JA, et al. Targeting muhidrug resistance in cancer [J]. Nat Rev Drug Discov,2006,5(3) :219 - 234.
  • 10Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of Pglycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells [ J]. Mol Pharmacol,1996,49(2) :311 -318.

同被引文献35

  • 1葛亮,钱海,高昊,陈跃坚,朱家壁.N-酰化壳聚糖的合成及其修饰多西他赛脂质体的体外性质研究[J].中国药科大学学报,2009,40(6):519-523. 被引量:3
  • 2翁静艳,杭太俊,张惠斌,黄文龙.RP-HPLC法测定HZ08含量及有关物质[J].中国新药杂志,2007,16(1):65-68. 被引量:3
  • 3YAN F, JIANG Y, LI YM, et al. Reversal of P-glycoprotein and muhidrug resistance-associated protein 1 mediated nuhidrug resistance in cancer cells by HZ08 isomers, Tetrataisohydroquinolin derivatives [ J ]. Biol Pharm Bull, 2008, 31 ( 6 ) : 1258 - 1264.
  • 4WENG JY, SONG M, HANGTJ, etal. Pharmacokinetics of HZ08 in rats by liquid chromatography-tandem mass spectrometry [J]. J Chromatogr B, 2007,856(1 -2) : 29 -34.
  • 5KRISHNA R, MAYER LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the Pharmacokinetics of anticancer drug[J]. Eur J Pharm Sci, 2000, 11(4) :265 -283.
  • 6CARSON SW, OUSMANOU AD, HOYLER SL. Emerging significance of P-glycoprotein in understanding drug disposition and drug interaction in psychopharmacology [ J ]. Psychopharmacol Bull, 2002, 36(1) :67 -81.
  • 7MATHENY CJ, LAMB MW, BROUWER KR, et al. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein mod- ulation [ J ]. Pharmacotherapy, 2001, 21 (7) :778 - 796.
  • 8AVENDASIO C, MENNDEZ JC. Inhibition of muhidurg resistance to antitumor agents (MDR)[J]. Curr Med Chem, 2002, 9 (2) :159 -193.
  • 9GOTTESMAN MM, FOJO T, BATES SE. Multidrug resistance in cancer: role of ATP-dependent transporters [ J ]. Nat Rev Cancer, 2002, 2(1) :48 -58.
  • 10LUM BL, GOSLAND MP. MDR expression in normal tissue. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors [ J ]. Hematol Oncol Clin North Am, 1995, 9 (2) : 319 -336.

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部